Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

Author： Santini Daniele   Vincenzi Bruno   Tonini Giuseppe  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.2, Iss.1, 2006-01, pp. : 1-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab

By  

Oncology Research and Treatment, Vol. 36, Iss. 10, 2013-09 ,pp. : 554-558

Karger

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite